Skip to content
Biophytis
LIVE HEALTHIER LONGER
Biophytis
  • Corporate
    • Executive Committee
    • Scientific Advisory Board
    • Boards of Directors
    • Code of Ethics
  • Our Science
    • BIO101
      • Posters & Publications
        • 2024
        • 2023
        • 2022
        • 2021
        • 2020
        • 2019
        • 2018
        • 2017
        • 2016
        • 2015
        • 2014
    • Macuneos (BIO201)
      • Posters & Publications
  • Pipeline
    • Pipeline
    • Key milestones in the development of BIO101
    • Sarcopenia: SARA clinical program
    • Obesity: OBA Clinical Program
    • COVID-19: COVA clinical program
    • Duchenne Muscular Dystrophy: MYODA clinical program
    • Age-related Macular Degeneration: MACA clinical program
  • Investors
    • Letter to shareholders
    • Live Stock Price
    • Corporate Presentation
    • General Meetings
      • 2024
      • 2023
      • 2022
      • 2021
      • 2020
    • AMF Regulated Information
    • SEC Filings
    • Financial Calendar
    • Convertible bonds
  • News
    • Press Releases
      • 2025
      • 2024
      • 2023
      • 2022
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
    • Biophytis in Media
  • Recruitment
  • Contact
    • Contact
    • Contact Information
    • Legal information
  • LinkedIn
  • Twitter
  • FR
  • EN
  • Corporate
    • Executive Committee
    • Scientific Advisory Board
    • Boards of Directors
    • Code of Ethics
  • Our Science
    • BIO101
      • Posters & Publications
        • 2024
        • 2023
        • 2022
        • 2021
        • 2020
        • 2019
        • 2018
        • 2017
        • 2016
        • 2015
        • 2014
    • Macuneos (BIO201)
      • Posters & Publications
  • Pipeline
    • Pipeline
    • Key milestones in the development of BIO101
    • Sarcopenia: SARA clinical program
    • Obesity: OBA Clinical Program
    • COVID-19: COVA clinical program
    • Duchenne Muscular Dystrophy: MYODA clinical program
    • Age-related Macular Degeneration: MACA clinical program
  • Investors
    • Letter to shareholders
    • Live Stock Price
    • Corporate Presentation
    • General Meetings
      • 2024
      • 2023
      • 2022
      • 2021
      • 2020
    • AMF Regulated Information
    • SEC Filings
    • Financial Calendar
    • Convertible bonds
  • News
    • Press Releases
      • 2025
      • 2024
      • 2023
      • 2022
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
    • Biophytis in Media
  • Recruitment
  • Contact
    • Contact
    • Contact Information
    • Legal information
  • LinkedIn
  • Twitter
  • FR
  • EN

JANUARY 19, 2021

Biophytis receives DMC recommendation for starting recruitment for Part 2 of its Phase 2-3 COVA study in COVID-19

Read the Press Release

Partager cet article
Share on LinkedInShare on LinkedIn Share on XShare on X Share on FacebookShare on Facebook Pin itShare on Pinterest Share on WhatsAppShare on WhatsApp

Post navigation

PreviousPrevious post:JANUARY 19, 2021NextNext post:January 20, 2021
  • Corporate
    • Executive Committee
    • Scientific Advisory Board
    • Boards of Directors
    • Code of Ethics
  • Our Science
    • BIO101
      • Posters & Publications
        • 2024
        • 2023
        • 2022
        • 2021
        • 2020
        • 2019
        • 2018
        • 2017
        • 2016
        • 2015
        • 2014
    • Macuneos (BIO201)
      • Posters & Publications
  • Pipeline
    • Pipeline
    • Key milestones in the development of BIO101
    • Sarcopenia: SARA clinical program
    • Obesity: OBA Clinical Program
    • COVID-19: COVA clinical program
    • Duchenne Muscular Dystrophy: MYODA clinical program
    • Age-related Macular Degeneration: MACA clinical program
  • Investors
    • Letter to shareholders
    • Live Stock Price
    • Corporate Presentation
    • General Meetings
      • 2024
      • 2023
      • 2022
      • 2021
      • 2020
    • AMF Regulated Information
    • SEC Filings
    • Financial Calendar
    • Convertible bonds
  • News
    • Press Releases
      • 2025
      • 2024
      • 2023
      • 2022
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
    • Biophytis in Media
  • Recruitment
  • Contact
    • Contact
    • Contact Information
    • Legal information
  • LinkedIn
  • Twitter
  • FR
  • EN
BIOPHYTIS
  • Corporate
    • Executive Committee
    • Scientific Advisory Board
    • Boards of Directors
    • Code of Ethics
  • Our Science
    • BIO101 (20-hydroxyecdysone)
    • Posters & Publications
    • Macuneos (BIO201)
    • Posters & Publications
  • Investors
    • Financial Calendar
    • AMF Regulated Information
  • Pipeline
    • Key programs milestones
    • COVID-19: COVA clinical program
    • Sarcopenia: SARA clinical program
    • Duchenne Muscular Dystrophy: MYODA clinical program
    • Age-related Macular Degeneration: MACA clinical program
  • Contact
    • Contact Information
    • Legal information
© Biophytis 2006-2025 - Mentions Légales
  • Corporate
    • Executive Committee
    • Scientific Advisory Board
    • Boards of Directors
    • Code of Ethics
Footer Colonne 1 - Anglais
Go to Top
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok